After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the safe route to a public company CEO role, or dive headfirst into the uncertain world of AI in healthcare. The pull toward AI proved irresistible.
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
Related Articles
Mayo Clinic Launches Two Companies To Support New Remote Monitoring Initiative
Medtech Insight: The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.April 13, 2021
Anumana’s ECG-AI® Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially availableMay 09, 2024
FDA grants breakthrough designation for Anumana’s ECG-AI algorithm
Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm…June 22, 2023
BOSTINNO’S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston’s innovation ecosystem ablaze.
Biz Journals: If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and…November 10, 2021


